Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of recurrent spontaneous miscarriages with hydroxychloroquine
2016-001330-97Phase 3Suspended
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hydroxychloroquine in recurrent miscarriage (RPL) and Hypercoagulability, sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoint: Live viable birth. Started Sep 2016; status: suspended.
02
Drugs
hydroxychloroquine
03
Conditions
recurrent miscarriage (RPL)Hypercoagulability
Beyond the preview
Go deeper on 2016-001330-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001330-97.